AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
REGULATORY UPDATE: CBER Announces 2024 Science Symposium
August 16, 2024
Resources Available to Assist Blood Community With Disaster Preparedness
August 08, 2024
REGULATORY UPDATE: BPAC Charter Renewed for Additional 2 Years
August 07, 2024